Pharmaceutical Executive Daily
New research suggests Ozempic may reduce biological age.
Top News
- FDA approval of Bayer's Lynkuet for menopausal hot flashes
- New research on Ozempic's potential to reduce biological age
- Novartis' $12 billion merger agreement to acquire Avidity Biosciences
The FDA has approved Bayer's Lynkuet, a dual neurokinin 1 and 3 receptor antagonist, for the treatment of moderate to severe vasomotor symptoms associated with menopause.
Lynkuet provides an important new therapeutic alternative for patients seeking relief from menopausal symptoms without estrogen exposure.
Author's summary: Ozempic may reduce biological age.
More News
- Biofuels and ethanol key to the future of U.S. agriculture - High Plains Journal
- The AI Gender Gap Paradox (SSIR)
- Kirby Smart: LSU coaches ‘borrow’ offices, adds context to Brian Kelly firing
- Venture Capital, Moonshots, and AI: The 2025 Tech Soap Opera
- Anthony Edwards has hamstring strain, to be re-evaluated in a week
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups